US · BIO · MEDICAL - DEVICES
Bio-Rad Laboratories, Inc. (BIO) intrinsic value and stock valuation
$358.90as of 2026-11-21 · Mkt cap 9.36B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Bio-Rad Laboratories, Inc. DCF and intrinsic value
InvestorsCraft values BIO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from BIO’s statements →
Bio-Rad Laboratories, Inc. Graham Number
Graham Number: $414.07d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Penumbra, Inc. (PEN) $319.12
- Charles River Laboratories International, Inc. (CRL) $314.32
- Align Technology, Inc. (ALGN) $155.17
- DaVita Inc. (DVA) $161.03
- Globus Medical, Inc. (GMED) $66.89
- Henry Schein, Inc. (HSIC) $83.52
- HealthEquity, Inc. (HQY) $94.75
- AptarGroup, Inc. (ATR) $140.08
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.8B | $2.92B |
| Operating income | $270.5M | $269M | $337.8M | $482.6M | $500.3M |
| Net income | $759.9M | -$-1.84B | -$-637.32M | -$-3.63B | $4.25B |
| EPSd | $27.9M | -$-65.37M | -$-21.82M | -$-121.77M | $140.8M |
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.5M | $669.5M |
| Capital expenditure | -$-157.6M | -$-189M | -$-156.68M | -$-114.16M | -$-133.75M |
| Free cash flow | $374.6M | $266.2M | $218.3M | $80.3M | $535.7M |
| Total assets | $10.6B | $9.36B | $12.3B | $13.5B | $17.8B |
| Total debt | $1.53B | $1.37B | $1.41B | $1.39B | $223.4M |
| Net debt | $999.2M | $886.6M | $1B | $953.9M | -$-247.41M |
| Total equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.7B |
| Cash and short-term investments | $1.54B | $1.66B | $1.61B | $1.79B | $869.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.8B | $2.92B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B |
| Research and development expenses | $256.9M | $295.9M | $247.4M | $256.9M | $260.6M |
| Selling, general and administrative expenses | $819.9M | $814M | $841.7M | $827.8M | $877.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.08B | $1.11B | $1.09B | $1.08B | $1.14B |
| Cost and expenses | $2.32B | $2.3B | $2.33B | $2.32B | $2.42B |
| Interest income | $95.5M | $82M | $100.9M | $58M | $18.9M |
| Interest expense | $49M | $48.9M | $49.4M | $38.1M | $1.55M |
| Depreciation and amortization | $205.4M | $151.6M | $145.9M | $177.2M | $137.6M |
| Ebitda | $1.25B | -$-2.14B | -$-654.8M | -$-4.49B | $5.59B |
| Operating income | $270.5M | $269M | $337.8M | $482.6M | $500.3M |
| Total other income/expenses, net | $725M | -$-2.61B | -$-1.19B | -$-5.19B | $4.95B |
| Income before tax | $995.5M | -$-2.34B | -$-850.1M | -$-4.7B | $5.45B |
| Income tax expense | $235.6M | -$-498.3M | -$-212.78M | -$-1.08B | $1.19B |
| Net income | $759.9M | -$-1.84B | -$-637.32M | -$-3.63B | $4.25B |
| Weighted average shares outstanding | $27.3M | $28.2M | $29.2M | $29.8M | $29.8M |
| Weighted average diluted shares outstanding | $27.3M | $28.2M | $29.2M | $29.8M | $30.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.54B | $1.66B | $1.61B | $1.79B | $869.9M |
| Net receivables | $472.5M | $452.5M | $489M | $494.6M | $423.5M |
| Inventory | $740.7M | $760M | $780.5M | $719.3M | $572.2M |
| Total current assets | $2.91B | $3.03B | $3.05B | $3.16B | $1.99B |
| Property, plant and equipment, net | $709.9M | $688.6M | $723.7M | $679.6M | $716.4M |
| Goodwill and intangible assets | $754.1M | $704.1M | $734.1M | $738.6M | $601.2M |
| Long-term investments | $6.1B | $4.84B | $7.7B | $8.83B | $14.4B |
| Total non-current assets | $7.67B | $6.33B | $9.25B | $10.3B | $15.8B |
| Total assets | $10.6B | $9.36B | $12.3B | $13.5B | $17.8B |
| Accounts payable | $129M | $122.3M | $144.6M | $135M | $141.9M |
| Short-term debt | $37.9M | $42.9M | $40.9M | $36.8M | $36.9M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $52.2M | $50.9M |
| Total current liabilities | $517M | $467.8M | $522.8M | $568.7M | $680.9M |
| Long-term debt | $1.49B | $1.33B | $1.36B | $1.35B | $186.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $2.61B | $2.33B | $3.04B | $3.32B | $3.43B |
| Capital lease obligations | $154.4M | $173.1M | $205.9M | $189.9M | $212.4M |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | $8.18B | $7.42B | $9.26B | $9.9B | $13.5B |
| Accumulated other comprehensive income (loss) | -$-189.1M | -$-538.2M | -$-336M | -$-466.82M | -$-175.55M |
| Total equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.7B |
| Total investments | $7.11B | $6.02B | $8.9B | $10.2B | $14.8B |
| Total debt | $1.53B | $1.37B | $1.41B | $1.39B | $223.4M |
| Net debt | $999.2M | $886.6M | $1B | $953.9M | -$-247.41M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $759.9M | -$-1.84B | -$-637.3M | -$-3.63B | $4.25B |
| Depreciation and amortization | $165.4M | $151.6M | $145.9M | $137.3M | $137.6M |
| Stock-based compensation | $58M | $62.3M | $61.3M | $60.9M | $51.2M |
| Change in working capital | $272.4M | -$-620.8M | -$-432.8M | -$-1.61B | $1.14B |
| Accounts receivable | $19.6M | $16.2M | $11.4M | -$-87.4M | -$-20.4M |
| Inventory | $68.9M | $8.5M | -$-46.3M | -$-158.8M | $46.1M |
| Accounts payable | -$-100K | -$-40.9M | -$-51.8M | -$-94.2M | $69.9M |
| Net cash provided by operating activities | $532.2M | $455.2M | $374.9M | $194.5M | $669.5M |
| Investments in property, plant and equipment | -$-157.6M | -$-165.6M | -$-156.68M | -$-112.78M | -$-133.75M |
| Acquisitions, net | -$-218.4M | $0.00 | $2.5M | -$-99.39M | -$-125.52M |
| Net cash used for investing activities | -$-189.7M | -$-160.2M | $20.2M | -$-1.21B | -$-797.38M |
| Common stock issued | $15.8M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-295.5M | -$-203.6M | -$-428.73M | -$-215.68M | -$-50M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-283.2M | -$-218.8M | -$-425.65M | $973.6M | -$-55.43M |
| Net change in cash | $40.3M | $85.4M | -$-30.18M | -$-36.59M | -$-195.98M |
| Cash at end of period | $532.2M | $489.8M | $404.4M | $434.5M | $471.1M |
| Operating cash flow | $532.2M | $455.2M | $374.9M | $194.5M | $669.5M |
| Capital expenditure | -$-157.6M | -$-189M | -$-156.68M | -$-114.16M | -$-133.75M |
| Free cash flow | $374.6M | $266.2M | $218.3M | $80.3M | $535.7M |
Line items
Line items
Line items
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- CEO
- Norman D. Schwartz
- Employees
- 7.45K
- Beta
- 1.08
Included in
Explore
Frequently asked questions
What is the intrinsic value of Bio-Rad Laboratories, Inc. (BIO)?
Bio-Rad Laboratories, Inc. (BIO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BIO undervalued?
BIO trades at a price of $358.90 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.